A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Trial Profile

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Fluorocyclopentenylcytosine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 15 May 2018 According to a Rexahn Pharmaceuticals media release, based on the review of the Safety Monitoring Committee (SMC), the company has entered in the second stage of the study. The subjects will be dosed at the highest (700 mg) recommended dose. Up to 40 patients will be enrolled into the second stage of the study
    • 12 Mar 2018 According to a Rexahn Pharmaceuticals media release, interim data readout expected in 2018.
    • 08 Nov 2017 According to a Rexahn Pharmaceuticals media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top